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Abstract
CD133 is a membrane molecule that has been, controversially, reported as a CSC marker in colorectal cancer (CRC). In this
study, we sought to clarify the expression and role of CD133 in CRC. Initially the size of the CD1332expressing (CD133+)
population in eight well-described CRC cell lines was measured by flow cytometry and was found to range from 0% to
.95%. The cell line HT29 has a CD133+ population of .95% and was chosen for functional evaluation of CD133 after gene
knockdown by RNA interference. A time course assay showed that CD133 inhibition had no significant effect on cell
proliferation or apoptosis. However, CD133 knockdown did result in greater susceptibility to staurosporine-induced
apoptosis (p=0.01) and reduction in cell motility (p,0.04). Since gene knockdown may cause ‘‘off-target’’ effects, the cell
line SW480 (which has a CD133+ population of 40%) was sorted into pure CD133+ and CD1332 populations to allow
functional comparison of isogenic populations separated only by CD133 expression. In concordance with the knockdown
experiments, a time course assay showed no significant proliferative differences between the CD133+/CD1332 populations.
Also greater resistance to staurosporine-induced apoptosis (p=0.008), greater cell motility (p=0.03) and greater colony
forming efficiency was seen in the CD133+ population than the CD1332 population in both 2D and 3D culture (p,0.0001
and p,0.003 respectively). Finally, the plasticity of CD133 expression in tumour cells was tested. Quantitative PCR analysis
showed there was transcriptional repression in the CD1332 population of SW480. Prolonged culture of a pure CD1332
population resulted in re-emergence of CD133+ cells. We conclude that CD133 expression in CRCs is associated with some
features attributable to stemness and that there is plasticity of CD133 expression. Further studies are necessary to delineate
the mechanistic basis of these features.
Citation: Elsaba TMA, Martinez-Pomares L, Robins AR, Crook S, Seth R, et al. (2010) The Stem Cell Marker CD133 Associates with Enhanced Colony Formation and
Cell Motility in Colorectal Cancer. PLoS ONE 5(5): e10714. doi:10.1371/journal.pone.0010714
Editor: Mikhail V. Blagosklonny, Roswell Park Cancer Institute, United States of America
Received February 9, 2010; Accepted April 27, 2010; Published May 19, 2010
Copyright:  2010 Elsaba et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by the University of Nottingham and CR-UK. Tarek Elsaba is a recipient of a PhD scholarship which has been provided by the
Egyptian government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Mohammad.Ilyas@nottingham.ac.uk
Introduction
Recent years have seen the emergence of the ‘‘cancer stem cell
hypothesis’’ which postulates that a minority population of cells
within a tumour consists of cancer stem cells (CSC) [1,2]. This
population is purportedly responsible for generating the bulk of the
tumour which consists of cells in varying degrees of differentiation.
The hierarchy of a tumour is thus thought to be similar to the tissue
from which the tumour originates and CSCs are deemed neoplastic
counterparts of stem cells in the normal tissue. In this respect, CSCs
would be expected to have a stem cell-like phenotype (generally
referred to as ‘‘stemness’’). This is characterised by features such as
limitless replicative ability, multipotency and resistance to apoptosis
[3]. The stem cell phenotype may also include cyto-protective
strategies such as ability to actively extrude dangerous substances
from the cell–a feature which may be the basis of resistance to
chemotherapeutic agents [3,4].
In parallel with the emergence of the cancer stem cell hypothesis,
there has been a growing interest in the isolation and study of CSCs.
A number of studies claim to have isolated CSCs from several
different tumour types such as brain [5,6], breast [7], colon [8,9],
hepatocellular carcinoma [10] and pancreatic cancer [11]. These
studies have used putative CSC markers to separate stem cells from
differentiating cells within a tumour. One common method of
separation is the dye elimination method (i.e. side population [12])
although identification of a number of cell surface markers (such as
CD24, CD44, CD166, and integrins) has allowed use of
fluorescence activated cell sorting (FACS) to isolate CSCs [13].
One marker consistently reported as a stem cell marker in tumours
of differing origins is CD133 (also known as Prominin 1).
The CD133 gene (PROM1) maps to chromosome 4p15 and
encodes a 120 kD transmembrane glycoprotein (ENSG00000007062).
The CD133 protein is pentaspan cell surface receptor although
neither its ligand nor its secondary messengers are known. It was
first recognized as a surface marker for haematopoietic stem cells
[14,15]. Later, it was used to recognize cancer stem cells in many
solid tumours arising in, for example, breast [13], pancreas [16]
and liver [17].
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in colorectal cancers (CRC) [8,9]. In these studies, CD133
expressing (CD133+) cells were isolated from primary CRCs and
were shown to have the ability to form tumours as xenografts in
nude mice; in contrast CD1332 cells from the same tumours were
shown to have very limited ability to form xenografts and even that
was attributed to contamination by CD133+ cells. Analysis of the
xenografts that were formed showed that the size of CD133+
population was similar to that seen in the primary tumour and,
furthermore, the ability to continuously propagate the xenografts
was tightly associated with CD133 expression. Subsequent studies,
however, have not validated these observations [18] and in one
study it has been reported that, in fact, the CD1332 population
has the greater colony forming ability [19]. Our study sought to
further clarify the expression and the role of CD133 in CRC. Two
approaches were used: (i) CD133 expression was functionally
evaluated in HT29 after gene knockdown and (ii) SW480
underwent cell sorting into a CD133+ population and a
CD1332 population followed by comparative functional analysis
of the two populations.
Materials and Methods
Tissue culture, flow cytometry and fluorescence activated
cell sorting
Eight human colorectal cancer cell lines (Caco2, DLD1, HT29,
Lovo, LS1034, SW480, SW620, SW837) were maintained as
previously described [20]. Identity of all cell lines was confirmed
by fingerprinting for mutations in KRAS, BRAF, PI3KCA, CDC4,
TP53 and testing microsatellite instability.
Evaluation of the size of the CD133 expressing (CD133+)
population in each cell line was undertaken by flow cytometry using
a phycoerythrin(PE)labelled antibody - CD133/1 (cloneAC133/1,
Miltenyi Biotec, UK). Cells were detached using non-enzymatic cell
dissociation solution (Sigma) and approximately 5610
5 cells were
incubated with antibody (diluted 1:100 in FACS wash (0.5% bovine
serum albumin; 2 mM NaN3; 5 mM EDTA)) for 15 minutes at
4uC. An isotype and concentration matched PE labelled control
antibody (Miltenyi Biotec, UK) was used and samples labelled with
this antibody were used to set the gating levels. After three 5 minute
washes with FACS wash, the cells were re-suspended and fixed in
solution containing FACS wash with 1% formaldehyde. Determi-
nation of percentage of CD133+ cells and sorting of cell lines into
CD133+/CD1332 populations were performed on an Epics Altra
flow cytometry machine (Beckman Coulter). The results were
analyzed using WinMDi 2.9 computer software.
For fluorescence activated cell sorting (FACS) of SW480, the cells
were labelled using the same protocol but without the final fixation
step. Inorder to evaluate plasticity ofCD133 expression,sortedcells
were maintained in culture for 3 weeks before undergoing
re-evaluation. For all other experiments, the CD133+/CD1332
populations were tested immediately after sorting.
RNA extraction, detection of splice variants and mRNA
quantification
Total RNA was extracted from cells using the RNeasy Mini Kit
(Qiagen) following the manufacturer’s instructions. Samples of
normal colonic mucosa were collected with full approval of the
local ethics committee (Oxford Research Ethics committee B,
REC reference C02.310). Written informed consent was obtained
from all patients whose samples were tested for CD133 expression
and splice variants. RNA was extracted and complementary DNA
(cDNA) was synthesized as previously described [20].
Two main splice variants have been described for CD133. The
larger variant AC133-1 (NM_006017) was identified first and
contains all exons [15]. The second variant, AC133-2, splices out
exon 4 which is 27 base pairs long and encodes a 9 amino acid
sequence in the first extracellular domain of CD133. Expression of
splice variants was tested by RT-PCR using an upstream primer in
exon 3 and a downstream primer in exon 5 (primer sequences
available from the authors). This would produce a product of 199
base pairs from AC133-1 and 172 bp from AC133-2. End point
PCR analysis was performed by viewing PCR products on agarose
gels. However, given that preferential amplification of the smaller
product may produce data artefacts, the study was repeated using
real-time PCR (with Sybr green as the reporter dye) on the
MX3005P thermal cycler (Stratagene, UK). Specificity of the PCR
was validated by bidirectional direct sequencing. The presence of
splice variants was tested in cDNA obtained from the CRC cell
lines, the sorted CD133+ and CD1332 populations of SW480 as
well as 10 samples of normal colonic mucosa
Sorted CD133+/2 populations underwent analysis of mRNA
levels by quantitative RT-PCR analysis using the standard curve
method. Analysis was performed in triplicate for each sample and
CD133 values were normalized to the housekeeping gene HPRT.
Each reaction was performed in a final volume of 25 mli na
MX3005P thermal cycler (Stratagene, UK). The data for Q-PCR
were analyzed using the MxPro-QPCR software.
Gene knockdown
Gene knockdown was achieved by transfecting HT29 cells
(shown to have high CD133 expression) with CD1332specific
small interfering RNA (siRNAs). Approximately 2610
5 cells were
seeded in 2 ml DMEM media with 10% FBS in 6 well plates
(Corning) 24 hours prior to transfection. Cells were transfected
with CD133-specific stealth siRNA duplexes (sequence: 59-GAG-
UCGGAAACUGGCAGAUAGCAAU-39, Invitrogen) at a final
concentration of 33 nM using Lipofectamine 2000 (Invitrogen) in
accordance with the manufacturer’s instructions. These are
henceforth annotated as HT29
CD1332. Controls consisted of cells
transfected with scrambled control siRNA (sequence: 59-GAGG-
GAACAGUCGGAUAGACCUAAU-39) and are henceforth an-
notated as HT29
ssc (scrambled siRNA control).
Western blotting
For Western blotting, lysates were prepared and quantified as
previouslydescribed [20].Samples(30 mg)weresubjected to Sodium
Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
using a 10% resolving polyacrylamide gel and transferred onto a
Hybond-PPVDFmembrane(AmershamBioscience).Afterblocking
with 5% Bovine Serum Albumin (BSA)/0.1% TPBS (Tween20 in
PBS solution) for 60 minutes, the membrane was then incubated
over night at room temperature with CD133 (C24B9) Rabbit mAB
(Cell Signaling) in a concentration of 1:1000. The membrane was
washed with 0.1% TPBS 3 times for 5 minutes each then incubated
for 1 h at room temperature with a horseradish peroxidase-linked
secondary antibody (Sigma Aldrich) (1:10000, anti-rabbit IgG)
diluted with 5% BSA/PBS containing 0.1% Tween20. After a
further 3 washes, the membrane was visualized enhanced chemilu-
minescence reagents (Thermo scientific) For a loading control, the
monoclonal Anti-b-actin antibody (Sigma Aldrich) in a dilution of
1:2000 against the b-actin protein was used.
Proliferation assays
A time course assay for proliferation was performed after gene
knockdown and after cell sorting. For HT29, each well of a 24 well
plate was seeded with 10
4 cells 24 hours after transfection with
CD133 and Colorectal Cancer
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10714CD133 and Colorectal Cancer
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10714either CD133 specific or scrambled control siRNA. Cell numbers
were assessed on days 1, 3 and 5. For SW480 the sorted CD133+
and CD1332 populations were seeded at 10
4 cells per well and cell
numbers assessed on days 1, 3, 5, 7 and 9. At least two independent
experiments, each in triplicate, were performed. A methylene blue
assay [21,22] was used to quantify numbers of adherent viable cells.
Stauropsorine induced apoptosis
Staurosporine was used to evaluate the resistance conferred by
CD133 to exogenous apoptotic stresses. For HT29, each well of a
96 well plate (Costar) was seeded with either HT29
CD1332 or
HT29
ssc cells 72 hours after transfection. Approximately 5610
4
cells were seeded per well and incubated with staurosporine
(Sigma) at a final concentration of 8 mM for 24 hours. After this
period, viable and apoptotic cells were measured. For SW480,
each well of a 96 well plate was seeded with 10
5 cells of the sorted
cells and staurosporine was added 24 hours later at a concentra-
tion of 8 mM. After another 24 hours, the numbers of viable cells/
apoptotic bodies were assessed. The assay was performed in
triplicate and repeated in at least two independent experiments.
2 dimensional (2D) and 3 (3D) dimensional colony
forming assay
The ability of isolated single CD133+ and CD1332 cells to
form colonies was tested in both 2 dimensional (2D) culture and 3
dimensional (3D) culture. For 2D culture, 300 freshly sorted cells
were seeded into individual wells of a 6 well plate and cultured for
14 days. The cells were then stained with methylene blue and
colonies containing more than 20 cells were counted. The
experiments were carried out in triplicate and on two occasions.
3D culture was performed to assess the colonogenic ability of the
sorted populations in non adherent conditions. Cells (2500 from
each population CD133+ and CD133-cells) were counted and
resuspended as single cells in 0.7% DNA grade agarose (Sigma
Aldrich).This was overlaid on a base of 1% DNA grade agar (Sigma
Aldrich) and both top and base layers were mixed with 2X DMEM.
Experiments were set up in triplicate and medium changed twice a
week. After two weeks, the number of colonies that developed
within each well was counted and visualized under a microscope
afterstaining with 0.05%crystalvioletfor1 hourandrepresentative
fields were photographed. For both 3D and 2D culture, percent
colonyforming efficiency (CFE) was calculated as follow, % CFE =
(Number of obtained colonies/Number of cultured cells) X 100
[23]. Log transformed values were then used for statistical analysis.
In vitro migration assay
Transwell cell migration assays were performed using a Boyden
chamber containing a polycarbonate filter with an 8 mm pore size
(Costar). Culture medium (600 ml) supplemented with 20% FBS
was added to the lower chamber and 2.5610
5 cells of the sorted
populations were added into the upper chamber (in 100 mlo f
culture medium supplemented with 10% FBS). The number of
cells migrating through the membrane was manually counted after
24 hours. Assays were performed in triplicate and on two separate
occasions. Cell migration was also measured using a cell wounding
assay performed in 6 well plates (Costar). Cells were grown to
confluence and then starved for 24 hours in serum free medium. A
sterile 200 ml pipette tip was used to create three separate parallel
wounds and migration of the cells across the wound line was
assessed after 24 hours. Photographs were taken using a charge-
coupled device (CCD) camera (Canon, Japan) attached to the
Figure 1. Evaluation of CD133+ populations by flow cytometry. Eight CRC cell lines were tested and showed varying size of the population of
CD133+ cells. (a) Sample flow cytometry images are shown for Caco2 (left panels, .95% positive cells) and SW837 (right panels). Analysis was
performed using AC133/1 antibody (top panel) and gating was performed for each cell line using an isotype control (bottom panel), PMTLin 1 is
photmultiplier tube linear 1 which indicates side scatter) (b) shows that in two cell lines there were no CD133+ cells identified whilst in two cell lines
nearly all cells were CD133+. The remaining cell lines had varying size population of CD133+ cells.
doi:10.1371/journal.pone.0010714.g001
Figure 2. Splice variants of CD133. Cell lines and normal mucosal samples were tested for expression of the two main CD133 splice variants by RT-
PCR with primers anchored on either side of the spliced out exon (exon 4). Sample data are shown which demonstrate only a single product was
identifiedwhenPCR productswereanalysedonboth(a)agarosegel and (b) the more sensitive Q-PCRtechnique usingSybr green asa reporter.M = size
marker, nc = negative control, * represents DLD1. (c) Sequencing of the products showed that exon 4 was spliced out of the coding sequence thus only
shorter splice variant (AC133-2) was being expressed. The sequence above the electropherogram is of AC133-1 with exon 4 shown between the lines.
doi:10.1371/journal.pone.0010714.g002
CD133 and Colorectal Cancer
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distance between the edges was measured at 6 equally distributed
points using ImageJ software [33] and then analysed using a two
tailed t-test. Experiments were repeated on two separate occasions.
Statistical analysis
Statistical analysis was undertaken using SPSS 13.0 Software.
All evaluations were done using unpaired two tailed Student’s T-
test. For studies involving cell and colony counting, cell numbers
were analysed. For studies with a numerical fluorescence output,
the raw fluorescence values were used.
Results
CD133 expressing populations in cell lines
The size of the CD133+ population was tested in 8 CRC cell
lines by flow cytometry and in each case approximately 500 000
cells were analysed. In two cell lines (DLD1 and SW837), CD133+
cells were not detectable. The size of CD133+ population was
found to be .95% in two cell lines (Caco2 and HT29). In the
remaining cell lines, a bimodal population was present with a
CD133+ population ranging from 32–64% (Figure 1).
Splice variants of CD133 in CRC cell lines and normal
mucosa
Expression of the two main splice variants of CD133 (AC133-1
and AC133-2) was tested by RT-PCR in both the cell lines and
samples of normal mucosa. Only one product was seen on agarose
gels which, on sequencing, was found to be the shorter AC133-2
splice variant from which exon 4 is spliced out (Figure 2a and 2c).
However, shorter PCR products undergo preferential amplifica-
tion and it is possible that larger products may be missed by both
agarose gel electrophoresis and sequencing (especially if present at
low levels). The analysis was refined by performing PCR using
SYBR green as a reporter dye. Evaluation of the dissociation curve
showed the presence of a single PCR product only (Figure 2b).
Knockdown of CD133
HT29 has a high level of CD133 expression. Cells were
transfected with either CD133 specific or scrambled control
siRNA and were tested 72 hours post transfection. Western blot
showed that the protein was virtually undetectable in the when
CD133 specific siRNA was used. In contrast, transfection of the
control siRNA has no effect on protein expression (Figure 3).
Association of CD133 expression with cell proliferation
We compared the proliferation rate between cells with high and
low CD133 levels using two experimental approaches. In HT29 the
CD133 protein was knocked down and cell numbers monitored for
5 days (Figure 4a) whilst SW480 was sortedinto CD133+/CD1332
populations and cell numbers were monitored over 9 days
(Figure 4b). Both experiments showed the same results i.e. there
was no significant difference between cells with high or low CD133
expression. Similarly, counts of floating apoptotic bodies over this
period did not show any difference (data not shown).
Association of CD133 expression with staurosporine
induced apoptosis and colony formation
A feature that may be expected in stem cells is resistance to
apoptosis following exogenous stress. Both experimental approaches
were used to test the effect of CD133 levels on resistance to apoptosis
when exposed to staurosporine for 24 hours. Concordant results
Figure 3. Knockdown of CD133. HT29 cells were transfected with
either CD133 specific siRNA (HT29
CD1332)o rs c r a m b l e dc o n t r o l
((HT29
ssc). Western blotting confirmed the loss of CD133 expression
by gene knockdown. b-Actin shows equal protein loading.
doi:10.1371/journal.pone.0010714.g003
Figure 4. Effect of CD133 on proliferation. Cell proliferation was
evaluated after knockdown of CD133 in HT29 (Figure 4a) and sorting of
SW480 into pure CD133+ and CD1332 populations (Figure 4b). A time
course assay was performed over several days with no association seen
between CD133 and cell numbers.
doi:10.1371/journal.pone.0010714.g004
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shows that after exposure to staurosporine there were fewer viable cells after transfection with CD133 specific siRNA (HT29
CD1332) than with
scrambled control (HT29
ssc) (p=0.01). There were no differences between the cells after exposure to DMSO. Figure 5b shows that the CD133+
population of SW480 showed cells showed significantly greater resistance than the CD1332 population (p=0.008). Figure 5c and 5d show CD133+
cells were significantly more clonogenic than CD1332 cells (p,0.0001 and p,0.003) in 2D and 3D culture respectively. Figures 5e (colonies formed
by CD133+ cells) and 5F (colonies formed by CD1332 cells) show that both CD133+ and CD1332 populations of SW480 were able to form colonies
from single cells (typical colonies are shown).
doi:10.1371/journal.pone.0010714.g005
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staurosporine resistance. Fewer viable HT29
CD1332 cells were
present than HT29
ssc cells (Figure 5a, p=0.01); conversely greater
numberofviablecellswerepresentinthesortedCD133+population
than the CD1332 population(Fig. 5b, p=0.008). There was
however no difference between cells when exposed to DMSO alone.
Another features of ‘‘stemness’’ is the ability to form colonies.
This was tested by growing single cells in soft agar for two weeks
(3D culture) and 2D culture and the sorted CD133 + and CD133 2
cells were compared. In both cases, colonies were visible after two
weeks but the number of colonies was significantly greater in
CD133 + cells (P,0.0001, and P,0.003) in 2D and 3D culture
respectively (Figure 5c and 5d).
Association of CD133 expression with cell migration
Comparative analysis of cell motility between cells with high
and low CD133 expression was tested by transwell migration
assays. Both experimental conditions produced concordant results.
Significantly fewer HT29
CD1332 cells migrated across the
membrane than HT29
ssc cells (Figure 6a, p=0.04). Conversely,
significantly larger numbers of CD133+ cells migrated than
CD1332 cells (Figure 6b, p=0.03). A cell wounding assay was
also used following gene knockdown which showed that the wound
edges were significantly closer in HT29
ssc cells than in
HT29
CD1332 cells (p,0.001) thereby confirming the relationship
between high CD133 expression and increased cell motility
(Figure 6c).
Figure 6. Effect of CD133 on cell motility. Transwell migration was measured after knockdown of CD133 in HT29 and sorting of SW480 into
CD133+/2 populations. Significantly fewer HT29
CD1332 cells migrated across the membrane than HT29
ssc cells (Figure 6a, p=0.04). Conversely, larger
numbers of sorted CD133+ cells migrated than CD1332 cells (Figure 6b, p=0.03). A wounding assay was also undertaken and gene knockdown was
associated with marked delay in closure of the wound which was visiually perceptible after only 24 hours (Figure 6c) and statistically significant
(p,0.001).
doi:10.1371/journal.pone.0010714.g006
CD133 and Colorectal Cancer
PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10714CD133 and Colorectal Cancer
PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10714Plasticity of CD133 expression in cell lines
The SW480 cell line was sorted into CD133+ and CD1332
populations which were maintained in standard tissue culture
conditions and underwent regular analysis by flow cytometry.
Immediate re-analysis showed that the CD133+ and CD1332
populations were, respectively, 97.6% and 99.9% pure (Figure 7a).
Quantitative PCR showed transcriptional repression of CD133 in
the CD1332 population and although CD133 mRNA was still
detectable, it was only at 15% of the level seen in the CD133+
population (Figure 8).
Prolonged culture resulted in both populations reverting to a
bimodal profile. The CD133+ population, after 3 weeks, consisted
of 70% CD133+ cells and 30% CD1332 cells, frequencies which
remained stable thereafter for at least 3 months. The findings run
counter to published reports in which pure populations of
CD133+ cells revert to normal ratio of CD133+/2 populations
[8]. The CD1332 cells developed a population of CD133+ cells
which, after 3 weeks, reached 17% but did not increase thereafter
(Figure 7b).
Discussion
The CD133+ population is variable in CRC cell lines
We screened large numbers of cells from eight well established
CRC cell lines by flow cytometry to quantify the size of the
CD133+ population. We found that, in two cell lines (DLD1 and
SW837) there were no detectable CD133+ cells, in two cell lines
(Caco2 and HT29) the CD133+ population was .95% of the total
tumour cells whilst the remaining cell lines had population sizes
ranging from 32%–64%. Our data are in agreement with studies
by letaet al. and Dalerba et al. [18,24] who reported similar levels
of CD133 expression in the cell lines HT29, Lovo and no
expression in DLD1. Our data are however discrepant with those
of O’Brien and Ricci-Vitiani [8,9], although the cause of this
discrepancy is unknown. One possibility is that our studies used
established cell lines whereas the other studies used novel cell lines
derived in their own laboratories. It is possible that prolonged
culture may cause maintained changes in CD133 regulation
although this in itself would suggest that CD133 expression is not a
very good marker of CSCs. Differences in technique may provide
another explanation although we used the same antibodies as
O’Brien and Ricci-Vitiani and we kept incubation times with the
primary antibody down to 15 minutes. Either way, our data have
unequivocally shown that in 4/8 cell lines, the CD133+ population
is either absent or comprises nearly the whole tumour cell
population. These data together with other data presented below,
lead us to conclude that CD133 is probably not a specific marker
of stem cells in CRC.
Only CD133 splice variant AC133-2 is expressed in
colonic tissue
Although a wide variety of splice variants have been described
for CD133, only one (termed AC133-1 and which was first to be
cloned) has been allocated a Reference Sequence number. This
contains the full length coding sequence whilst a second splice
variant (AC133-2, the second to be cloned) appears to splice out
exon 4. Our analysis of 8 CRC cell lines and 10 samples of normal
mucosa, using both end-point and real-time methodologies,
identified only variant AC133-2. This would be consistent with
the study by Yu et al. [25] in which AC133-2 was reported as
being the splice variant which is present in many stem cell
compartments whilst AC133-1 is limited to foetal brain and
skeletal muscle.
CD133 expression is associated with some features of the
stem cell phenotype
In order to evaluate the function of CD133, the cell line HT29
was tested after knockdown of CD133 by RNA interference. This
method can also produce ‘‘off-target’’ effects and so a comple-
mentary approach was used to separate SW480–a cell line with a
CD133+ population of 40% - into pure CD133+ and CD1332
populations. Both types of experiments yielded similar results.
Firstly, levels of CD133 did not appear to alter cell proliferation or
apoptosis. There were however significant differences in the
features which may be regarded as part of the stem cell phenotype.
Thus high levels of CD133 were associated with increased
clonogenicity and resistance to staurosporine induced apoptosis.
The latter may be due to an innate resistance to apoptosis (possibly
mediated by such reported associations as between CD133
expression and anti-apoptotic genes such as FLIP (Caspase 8
inhibitor) and Bcl-2 [26]. Alternatively, it may be due to enhanced
cytoprotective strategies such as the ability to actively extrude toxic
substances from the cytoplasm [3].
Another feature we found to be associated with CD133
expression was enhanced cell motility. Other studies have
suggested a role for CD133 in cell motility since it is classically
expressed in membrane protrusions [27,28]. In certain situations,
such as embryogenesis and wound healing, stem cells need to
acquire features of motility. In CSCs, features of enhanced motility
may allow invasion and metastasis to occur–a notion supported by
the study of Rappa et al which found CD133 expression was
associated with metastasis in melanoma cells [29]. Our data do,
however, contradict those of Horst et al. [30] who did not find that
CD133 expression was associated with cell motility in Caco2. We
Figure 7. Plasticity of CD133 expression. SW480 was sorted into CD133 positive and negative populations which were then cultured separately.
(a) Gating was set so that only the extreme populations were collected which, on immediate retesting, were shown to be very pure populations. (b)
After prolonged culture, both of the sorted populations became biphasic. The ratios of the CD133+ and CD1332 cells became stable after three
weeks and did not change after that (although they were not the same as the original parental cell line).
doi:10.1371/journal.pone.0010714.g007
Figure 8. mRNA level in sorted populations. Q-RT-PCR analysis of
the sorted populations showed that there was transcriptional
repression of CD133 in the CD1332 population (although low levels
of mRNA were still detectable).
doi:10.1371/journal.pone.0010714.g008
CD133 and Colorectal Cancer
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be due to technical differences between laboratories, differences in
cell lines or differences in the duplex sequence used for gene
knockdown.
CD133 shows plasticity of expression in CRC cell lines
We used FACS to sort SW480 into pure CD133+ and CD1332
populations and, by mRNA quantification, showed that this was
due to transcriptional repression rather than changes in glycosyl-
ation. The mechanistic basis of inhibiting CD133 expression is
uncertain. Epigenetic silencing due to hypermethylation of CD133
promoter has been reported as a means of controlling CD133
expression [31]. Alternatively other mechanisms such as mRNA
degradation may be involved. Prolonged culture of pure CD133+/
CD1332 populations resulted in both populations reverting to a
bimodal pattern although in neither case did the pattern revert to
that of the original cell line. Thus, after 3 months, the cultured
pure CD133+ population developed a CD133+/CD1332 split of
70%/30% respectively. These data are consistent with other
studies showing that tumours derived from CD133+ populations
ultimately become bimodal. However, it is uncertain why the
CD133+ population did not revert to 40% as seen in the original
SW480 cell line.
The cultured pure CD1332 population developed a stable
CD133+ population of around 17%. The study by O’Brien found
that CD1332 sorted populations could induce tumours containing
a CD133+ population and attributed this to contamination of the
CD1332 cells by CD133+ cells. We think that contamination is
unlikely to be an explanation in our case as our time-course studies
did not show any difference in rates of proliferation between
CD133+ and CD1332 cells. Another possibility is that CD133
was re-induced in these cells. Since CD133 mRNA was detected in
the CD1332 cells, it shows that a low level of transcriptional
activity may still have been occurring in cells which were negative
for protein expression. This would fit with data from animal
studies demonstrating that transit amplifying cells (which lie
beyond the stem cell compartment) can re-acquire stem cell
properties in the small intestine under appropriate conditions [32].
If this is the case, then it would question the existence of CSCs
since, by extension, non-stem cells within a tumour could
theoretically acquire stem cell features.
In summary we have shown that there is only one CD133 splice
variant expressed in colorectal tissues and there is plasticity of its
expression. There is marked variation in the size of the CD133+
population within CRC cell lines although, given that some cell
lines have no CD133+ cells and CD1332 cells from bimodal
populations can be clonogenic, it is unlikely that CD133 is a
specific stem cell marker. However CD133 expression is associated
with some attributable to stemness and the mechanistic basis of
these warrants further investigation.
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